{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-200760","form_type":"8-K","ticker":"MAZE","cik":"0001842295","company_name":"Maze Therapeutics, Inc.","filed_at":"2025-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.306240+00:00","generated_at":"2026-05-17T06:54:13.061867+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Maze raises $150M at premium; Phase 1 MZE782 data positive, Phase 2 in 2026","bullets":["Oversubscribed private placement of $150M gross proceeds at $16.25/share (premium to last close), closed Sept 12.","Issued 4M shares and 5.23M pre-funded warrants; investors include Frazier, Deep Track, Janus Henderson, others.","Phase 1 MZE782 in 112 healthy volunteers: 42-fold urinary Phe excretion, no SAEs, well tolerated.","Dose-dependent eGFR dip similar to SGLT2 inhibitors observed; plans for Phase 2 in PKU and CKD in 2026.","Proceeds to advance MZE829 in APOL1 kidney disease, MZE782 Phase 2, Compass platform, and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-200760","json":"https://secwatch.observer/filing/0001193125-25-200760.json","markdown":"https://secwatch.observer/filing/0001193125-25-200760.md","text":"https://secwatch.observer/filing/0001193125-25-200760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/0001193125-25-200760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/d90404d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:54:13.061867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a072aa1680792e1d46ec65d16088de7a8c2d7d9","claim":"Maze Therapeutics, Inc. issued up to an aggregate of 5,231,090 shares of Common Stock of warrant to certain institutional and accredited investors for $16.249 per Pre-Funded Warrant.","evidence_excerpt":"Placement ”) an aggregate of (i) 4,000,002 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $16.25 per share and (ii) in lieu of shares of Common Stock for certain Investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 5,231,090 shares of","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/0001193125-25-200760-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"up to an aggregate of 5,231,090 shares of Common Stock"},{"label":"Purchaser","value":"certain institutional and accredited investors"},{"label":"Consideration","value":"$16.249 per Pre-Funded Warrant"}],"fact_type":"equity_issuance"},{"claim_id":"33618a573d9078e4264c49362fb0c7c4cdd18388","claim":"Maze Therapeutics, Inc. issued 4,000,002 shares of common stock to certain institutional and accredited investors for $16.25 per share.","evidence_excerpt":"Placement ”) an aggregate of (i) 4,000,002 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $16.25 per share and (ii) in lieu of shares of Common Stock for certain Investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 5,231,090 shares of","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/0001193125-25-200760-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"4,000,002 shares"},{"label":"Purchaser","value":"certain institutional and accredited investors"},{"label":"Consideration","value":"$16.25 per share"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}